RecruitingPhase 2NCT07091734
Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024
Studying Lipodystrophy due to peptidic growth factors deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Michigan
- Principal Investigator
- Elif Oral, MDUniversity of Michigan
- Intervention
- Tirzepatide(drug)
- Enrollment
- 32 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- University of Michigan, Ann Arbor, Michigan, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07091734 on ClinicalTrials.govOther trials for Lipodystrophy due to peptidic growth factors deficiency
Additional recruiting or active studies for the same condition.
See all trials for Lipodystrophy due to peptidic growth factors deficiency →